A Study to Examine Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients With Type 2 Diabetes

NCT00612794 · Completed

Last updated 2026-05-28

This clinical trial tested the safety and tolerability of a weekly injectable medication called exenatide in Japanese adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 30 people

Who can join Ages 20–75 · all sexes

Timeline Started 2007-09 · est. completion 2008-05

Where 4 sites · Japan

What this study is testing ClinicalTrials.gov NCT00612794 ↗

Description as written by the study sponsor.

Exenatide twice daily has been studied in Japanese type 2 diabetes patients. A once-weekly version of exenatide is currently being evaluated. Study GWBW is the first study of exenatide once weekly in Japanese patients. This study is designed to evaluate safety and tolerability of exenatide once weekly in Japanese patients and determine whether the dose selected for US and European development is appropriate for Japanese patients with Type 2 diabetes.

Treatments tested

exenatide once weekly Drug

subcutaneous injection, once weekly
placebo Drug

subcutaneous injection, once weekly

Main thing measured	To assess the safety and tolerability of exenatide administered once weekly by subcutaneous (SC) injection in subjects with type 2 diabetes mellitus.
Sponsor	AstraZeneca
Conditions studied	Type 2 Diabetes
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00612794 ↗